ERBB2 G778_P780dup

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma2
ERBB2 G778_P780dup	Afatinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID1890 A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were ide… (full text at CIViC) PMID 22325357 · De Grève et al., 2012 · Open in CIViC	civic
ERBB2 G778_P780dup	Dacomitinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID1048 In this phase II study (NCT00818441) of dacomitinib in HER2 amplified or mutant NSCLC tumors, three of 26 patients with HER2 p.P780_Y781insGSP or p.M774delinsWLV showed partial responses of duration b… (full text at CIViC) PMID 25899785 · Kris et al., 2015 · Open in CIViC	civic

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Lung Adenocarcinoma2

ERBB2 G778_P780dup

Afatinib

Predictive

Supports Sensitivity Response

accepted

EID1890

A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were ide… (full text at CIViC)

PMID 22325357 · De Grève et al., 2012 · Open in CIViC

civic

ERBB2 G778_P780dup

Dacomitinib

Predictive

Supports Sensitivity Response

accepted

EID1048

In this phase II study (NCT00818441) of dacomitinib in HER2 amplified or mutant NSCLC tumors, three of 26 patients with HER2 p.P780_Y781insGSP or p.M774delinsWLV showed partial responses of duration b… (full text at CIViC)

PMID 25899785 · Kris et al., 2015 · Open in CIViC

civic

Lung Non-Small Cell Carcinoma4
ERBB2 Amplification OR ERBB2 A775_G776insIVMA OR ERBB2 A775_G776insYVMA OR ERBB2 G778_P780dup OR ERBB2 G778-779 insCPG OR ERBB2 G776_V777>VCV OR ERBB2 G776delinsVC OR ERBB2 L755P OR ERBB2 V659E OR ERBB2 S310F OR ERBB2 S335C	Ado-trastuzumab Emtansine Regimen	Predictive	B	Supports Sensitivity Response	3	submitted	EID11323 In this phase II basket trial, 18 patients with advanced HER2-mutant lung adenocarcinomas were enrolled to receive ado-trastuzumab emtansine at 3.6 mg/kg intravenously every 3 weeks until progression.… (full text at CIViC) PMID 29989854 · Li et al., 2018 · Open in CIViC	civic
ERBB2 G778_P780dup	Dacomitinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID1892 Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification. Two patients were identified with identical HER2 p.G778_P780dup mutations (p. P780_Y781i… (full text at CIViC) PMID 25899785 · Kris et al., 2015 · Open in CIViC	civic
ERBB2 G778_P780dup	Trastuzumab Deruxtecan	Predictive	A	Supports Sensitivity Response	3	accepted	EID11762 In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC) PMID 37694347 · Goto et al., 2023 · Open in CIViC	civic
ERBB2 Y772_A775dup OR ERBB2 G778_P780dup OR ERBB2 G776delinsVC OR ERBB2 V659E OR ERBB2 S310F OR ERBB2 G776delinsLC	Sevabertinib	Predictive	A	Supports Sensitivity Response	4	accepted	EID12807 In an open-label, multicenter, multicohort phase 1–2 study of non-small cell lung carcinoma (NCT05099172; total n = 209), single-agent sevabertinib 20 mg BID demonstrated clinically meaningful activit… (full text at CIViC) PMID 41104928 · Le et al., 2025 · Open in CIViC	civic

Lung Non-Small Cell Carcinoma4

ERBB2 Amplification OR ERBB2 A775_G776insIVMA OR ERBB2 A775_G776insYVMA OR ERBB2 G778_P780dup OR ERBB2 G778-779 insCPG OR ERBB2 G776_V777>VCV OR ERBB2 G776delinsVC OR ERBB2 L755P OR ERBB2 V659E OR ERBB2 S310F OR ERBB2 S335C

Ado-trastuzumab Emtansine Regimen

Predictive

Supports Sensitivity Response

submitted

EID11323

In this phase II basket trial, 18 patients with advanced HER2-mutant lung adenocarcinomas were enrolled to receive ado-trastuzumab emtansine at 3.6 mg/kg intravenously every 3 weeks until progression.… (full text at CIViC)

PMID 29989854 · Li et al., 2018 · Open in CIViC

civic

ERBB2 G778_P780dup

Dacomitinib

Predictive

Supports Sensitivity Response

accepted

EID1892

Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification. Two patients were identified with identical HER2 p.G778_P780dup mutations (p. P780_Y781i… (full text at CIViC)

PMID 25899785 · Kris et al., 2015 · Open in CIViC

civic

ERBB2 G778_P780dup

Trastuzumab Deruxtecan

Predictive

Supports Sensitivity Response

accepted

EID11762

In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

civic

ERBB2 Y772_A775dup OR ERBB2 G778_P780dup OR ERBB2 G776delinsVC OR ERBB2 V659E OR ERBB2 S310F OR ERBB2 G776delinsLC

Sevabertinib

Predictive

Supports Sensitivity Response

accepted

EID12807

In an open-label, multicenter, multicohort phase 1–2 study of non-small cell lung carcinoma (NCT05099172; total n = 209), single-agent sevabertinib 20 mg BID demonstrated clinically meaningful activit… (full text at CIViC)

PMID 41104928 · Le et al., 2025 · Open in CIViC

civic

Malignant Breast Neoplasm1
ERBB2 G778_P780dup	Neratinib	Predictive	D	Supports Sensitivity Response	4	accepted	EID285 In MCF10A cell lines, the in-frame insertion of a three amino acids at position (GSP) 780 was shown to be sensitive to neratinib. PMID 23220880 · Bose et al., 2013 · Open in CIViC	civic

Malignant Breast Neoplasm1

ERBB2 G778_P780dup

Neratinib

Predictive

Supports Sensitivity Response

accepted

EID285

In MCF10A cell lines, the in-frame insertion of a three amino acids at position (GSP) 780 was shown to be sensitive to neratinib.

PMID 23220880 · Bose et al., 2013 · Open in CIViC

civic

Evidence by cancer (7 items)

Clinical significance (0)